HemaCare Corporation Stock

HEMA

US4234981045

Healthcare Facilities & Services

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.08%	+0.24%

20-06-02	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
20-01-21	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI

on all subscriptions*

Exceptional extension!

Enjoy this offer

* See conditions under "Our services"

Valuation: HemaCare Corporation

Market Cap	346M 302M 279M 261M 490M 32.67B 493M 3.32B 1.29B 16.06B 1.3B 1.27B 55.8B	P/E 2017	8.18x	P/E 2018	27.6x
Enterprise Value	336M 293M 271M 253M 476M 31.73B 479M 3.23B 1.25B 15.6B 1.26B 1.23B 54.2B	EV / Sales 2017	1.29x	EV / Sales 2018	4.03x
Free-Float	94.17%	Yield 2017 *	-	Yield 2018	-

* Estimated data More valuation ratios

Latest news : HemaCare Corporation

20-06-02	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
20-01-21	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI
20-01-02	Charles River Laboratories International, Inc. completed the acquisition of HemaCare Corporation.	CI
19-12-15	Charles River Laboratories International, Inc. entered into a definitive agreement to acquire HemaCare Corporation for approximately $380 million.	CI
19-11-19	HemaCare Expands Its Product Portfolio with GMPrime™ Bone Marrow Aspirate	CI
19-08-27	HemaCare Corporation and Vital River Partner to Provide Human-Derived Biological Material to China	CI
19-08-20	Hemacare Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	CI
19-03-26	HemaCare Corporation Reports Earnings Results for the Year Ended December 31, 2018	CI
18-12-19	HemaCare Corporation announced that it has received $4.999999 million in funding from OBF Investments LLP	CI
18-12-06	HemaCare Corporation Moves its Global Headquarters to Northridge, California	CI
18-11-14	HemaCare Corporation Provides Starting Material for Three FDA Approved Cellular Therapies	CI
18-08-21	HemaCare Corporation Reports Unaudited Earnings Results for the Six Months Ended June 30, 2018	CI
18-07-17	HemaCare Corporation Announces Executive Appointments	CI

More news

Press Releases: HemaCare Corporation

19-12-16

HEMACARE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of HEMA and Encourages Investors to Contact the Firm

More press releases

Managers and Directors: HemaCare Corporation

Manager	Title	Age	Since
Colin S. Dunn CEO	Chief Executive Officer	-	-
Samira Amini DFI	Director of Finance/CFO	-	-
Maria Pia Muniz COO	Chief Operating Officer	-	2002-12-31

Director	Title	Age	Since
Colin S. Dunn BRD	Director/Board Member	-	-
Samira Amini BRD	Director/Board Member	-	-
Emily Nekimken BRD	Director/Board Member	-	-

More insiders

Other Healthcare Facilities & Services

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMACARE CORPORATION	-.--%	+0.08%	-	-	346M
CVS HEALTH CORPORATION	+0.36%	+0.34%	+51.27%	+45.21%	129B
HCA HEALTHCARE, INC.	+2.04%	-3.38%	+1.27%	+29.83%	83.63B
FRESENIUS SE & CO. KGAA	+1.83%	+3.20%	-4.21%	+58.83%	25.49B
QUEST DIAGNOSTICS INCORPORATED	+1.97%	-2.88%	+8.64%	+38.00%	21.43B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.47%	-2.61%	-15.07%	-27.05%	19.95B
TENET HEALTHCARE CORPORATION	+0.15%	-2.29%	+6.06%	+129.37%	15.4B
REDE D'OR SÃO LUIZ S.A.	-0.65%	-1.38%	-3.14%	+0.72%	14.5B
DAVITA INC.	+0.93%	+1.04%	+54.88%	+116.06%	13.46B
FRESENIUS MEDICAL CARE AG	+1.35%	+1.75%	-10.75%	-6.89%	12.68B
Average	+0.75%	-0.66%	+9.88%	+42.67%	33.61B
Weighted average by Cap.	+0.90%	-1.28%	+21.32%	+40.47%

See all sector performances

Charles River Laboratories Cell Solutions, Inc. is a cell sourcing provider for developers of cell therapies and basic research. The Company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. It offers a comprehensive and integrated portfolio of drug development products and services available from a single global provider, spanning the continuum from early research to the support of marketed products. Its products and services include Research Models & Services, Discovery Services Safety Assessment, Laboratory Sciences, Cell and Gene Therapy CDMO Solutions, Biologics Testing Solutions, Avian Vaccine Services, QC Microbial Solutions, Scientific & Regulatory Advisory Services, and Scientific Staffing, Training & Operations Support.

Employees

Sector

Healthcare Facilities & Services

More about the company

Stock Market
Stocks
HEMA Stock

-40%: Exceptional extension

SEIZE THE OFFER!

	2017	2018
Net sales	20.21M 17.66M 16.34M 15.25M 28.62M 1.91B 28.83M 194M 75.53M 939M 75.89M 74.24M 3.26B	28.51M 24.91M 23.04M 21.5M 40.37M 2.69B 40.67M 274M 107M 1.32B 107M 105M 4.6B
Net income	4.43M 3.87M 3.58M 3.34M 6.28M 419M 6.32M 42.57M 16.56M 206M 16.64M 16.28M 715M	4.52M 3.95M 3.65M 3.41M 6.4M 427M 6.44M 43.37M 16.88M 210M 16.96M 16.59M 729M
Net Debt	-9.06M -7.92M -7.32M -6.83M -12.83M -856M -12.92M -87.01M -33.85M -421M -34.01M -33.27M -1.46B	-9.9M -8.65M -8M -7.47M -14.02M -935M -14.12M -95.06M -36.99M -460M -37.16M -36.35M -1.6B

HemaCare Corporation Stock

Stocks

HEMA

US4234981045

Healthcare Facilities & Services

Valuation: HemaCare Corporation

Latest news : HemaCare Corporation

Press Releases: HemaCare Corporation

Managers and Directors: HemaCare Corporation

Other Healthcare Facilities & Services

Financials

Company Profile